MesenCure
MesenCure
An investigational, allogeneic cell therapy currently being evaluated for its potential to modulate inflammation and promote tissue repair. Derived from mesenchymal cells obtained from healthy donors, MesenCure undergoes a proprietary expansion and priming process designed to enhance its therapeutic properties. It is being studied in clinical trials for its potential application in treating respiratory distress.
What Sets MesenCure Apart?
- Proprietary expansion and priming process designed to boost the potency without genetic modifications
- Scalable bioprocess designed for high-yield GMP manufacturing
- Single-donor cell banks are expected to support large-scale production, subject to clinical validation
- Fresh, viable, and ready-to-use cell formulation avoids cryopreservation and loss of potency.
In preclinical studies, MesenCure was observed to reduce immune cell infiltration into the lungs and was associated with the resolution of pneumonia within 24 hours.
Clinical Trial Milestones:
MesenCure was evaluated in a Phase II clinical trial in severely ill patients with respiratory distress due to COVID-19 pneumonia.
In this trial, patients receiving MesenCure, in addition to the standard-of-care (SOC), were observed to experience:
- A 68% lower mortality rate compared to patients receiving SOC alone.
- A 57% reduction in the need for invasive ventilation compared to the SOC group.
- A 38% shorter average hospital stay for patients with longer than 7 days, compared to SOC patients
Phase III clinical trial:
In February 2025, the U.S. Food and Drug Administration (FDA) authorized the Company to proceed with a Phase III clinical trial to evaluate MesenCure for treating severely ill patients affected by respiratory distress due to COVID-19 pneumonia.
The Company is working on amending the clinical protocol to broaden the scope of the Phase III trial to include patients with respiratory distress from all causes, including ARDS, pending FDA clearance.
Before MesenCure treatment, a median of 53% of the patients’ lung area was congested with inflammatory infiltrates, which obstructed breathing (six representative patients are presented below).
One month after MesenCure treatment, breathing is normal, and pneumonia has dramatically reduced to a median of 0% coverage of the lung area (p < 0.0001)
Individual patient outcomes may vary, and actual results may differ. This application Remains subject to ongoing clinical evaluation and further research.
MesenCure: Preclinical Evidence Supporting Potential in ARDS
Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening condition characterized by widespread lung inflammation and fluid accumulation, often requiring intensive care and mechanical ventilation. ARDS affects millions of patients worldwide each year, and current treatments are largely supportive, underscoring the need for new therapeutic approaches.
MesenCure has been evaluated in preclinical models of pneumonia and ARDS following acute lung injury (ALI) induced by biological or chemical agents to investigate its potential to modulate inflammation and support lung tissue repair.
- In a biologically induced ALI model using lipopolysaccharide (LPS) toxin, MesenCure was associated with reduced lung edema and inflammatory cell infiltration1 [PMC8111922].
- In a lethal ALI model induced by the chemical toxin bleomycin, MesenCure was linked to improved survival and respiratory function.
In collaboration with the Israeli Institute for Biological Research, MesenCure was observed to reduce immune infiltration and support lung epithelial recovery in a ricin-induced ALI model2.
MesenCure: Preclinical Evidence Supporting Potential for Cancer-Related Inflammatory Complications
Certain cancer therapies, including immunotherapies, can lead to excessive immune activation and serious inflammatory complications, such as cytokine release syndrome (CRS). CRS has been reported in up to 78% of patients receiving CAR-T cell therapies, with severe cases occurring in approximately 27%.
MesenCure has been evaluated in preclinical studies to explore its potential to modulate immune responses and mitigate severe inflammation-related complications associated with cancer treatments.
- In a preclinical study conducted at The Jackson Laboratory USA (JAX), MesenCure was observed to regulate systemic hyper-immunity in a humanized CRS model induced by CAR-T cell therapy3.
- In a separate preclinical model, MesenCure was associated with improved survival following acute kidney and liver injuries induced by exposure to high-dose chemotherapy (cisplatin)
"We continue to advance research on MesenCure to investigate its potential in addressing conditions associated with acute inflammation and tissue damage."
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
